Drug Eluting Peripheral Stents Market Size, Share, and Growth Forecast, 2026 - 2033

The global drug eluting peripheral stents market size is likely to be valued at US$2.1 billion in 2026 and is expected to reach US$3.4 billion by 2033, growing at a CAGR of 7.3% between 2026 and 2033, driven by the rising burden of peripheral artery disease, population aging, increasing diabetes prevalence, and continued preference for minimally invasive vascular intervention. The market is entering a phase in which clinical durability, vessel-specific performance, drug-release control, and regulatory evidence increasingly determine product adoption.

Drivers - Rising Peripheral Artery Disease Burden and Demographic Risk

The growing prevalence of peripheral artery disease (PAD) is increasing the need for effective vascular treatments. Population aging, diabetes, and other cardiovascular risk factors are contributing to the rising burden of the disease. Patients with advanced PAD may require endovascular revascularization when medication and lifestyle changes alone cannot adequately manage their symptoms or restore blood flow.

Drug-eluting peripheral stents support this treatment approach by maintaining vessel patency while releasing medication that helps limit tissue growth and restenosis. Their use is particularly relevant for patients with symptomatic disease who require minimally invasive intervention. As awareness, diagnosis, and access to vascular care improve, demand for endovascular procedures is expected to increase. However, market growth will depend on the number of patients who require stenting, as treatment decisions vary according to disease severity, lesion characteristics, and individual clinical needs.

Advancements in Drug Delivery and Limb-Salvage Technologies

Advances in stent design and localized drug delivery are expanding treatment options for peripheral artery disease. Manufacturers are refining coating technologies, drug-release mechanisms, scaffold materials, and delivery systems to improve device performance across different vascular anatomies. Boston Scientific's Eluvia uses a polymer-based system to deliver paclitaxel, while Cook Medical's Zilver PTX features a polymer-free drug coating. These approaches reflect different strategies for controlling drug delivery and supporting long-term vessel patency.

Innovation is also extending into below-the-knee disease, where treatment can be challenging because of small vessel diameters and complex lesions. In 2024, the FDA approved Abbott's Esprit BTK Everolimus Eluting Resorbable Scaffold System for patients with chronic limb-threatening ischemia. The technology combines temporary vessel support with localized drug delivery. The subsequent approval of a longer scaffold configuration in 2026 expanded its treatment options. These developments are encouraging competition around vessel-specific solutions, improved deliverability, and long-term clinical outcomes.

Restraints - Clinical Evidence and Regulatory Complexity

The need to demonstrate long-term safety and effectiveness remains a major barrier to market expansion. Peripheral artery disease varies considerably in severity, lesion length, vessel diameter, calcification, and anatomical location. A device that performs well in one group of patients may not deliver the same outcomes in another. Manufacturers must therefore establish that their products are appropriate for specific clinical applications and support their claims with reliable evidence.

Regulatory requirements add to the time and cost of product development. In Europe, the Medical Device Regulation requires robust clinical documentation, post-market surveillance, and continued assessment of device performance. Manufacturers must also manage differences in reimbursement and procurement across individual countries. Drug-eluting stents face competition from drug-coated balloons, bare-metal stents, atherectomy devices, and surgical bypass. These alternatives can limit adoption when clinicians consider them more appropriate for a particular lesion or patient. Continued investment in clinical research, regulatory compliance, and physician education is essential for maintaining market access.

Opportunities - Expansion into Below-the-Knee Disease and Chronic Limb-Threatening Ischemia

Below-the-knee intervention offers an important growth opportunity as manufacturers develop technologies for complex peripheral vascular disease. Chronic limb-threatening ischemia can cause persistent pain, nonhealing wounds, tissue damage, and an increased risk of amputation. Restoring blood flow is therefore a key treatment objective for suitable patients. However, treating smaller vessels and complex lesions presents technical challenges, creating demand for devices that combine effective drug delivery with appropriate mechanical support.

The development of drug-eluting resorbable scaffolds is opening new possibilities in this area. Abbott's Esprit BTK platform illustrates the potential of combining temporary scaffolding with localized drug delivery. Further advances in scaffold design, coating technology, and delivery systems could expand treatment options for patients with challenging infrapopliteal disease. Manufacturers that demonstrate durable clinical benefits and reliable device performance may be well positioned to address this unmet need. Adoption will depend on clinical outcomes, physician experience, reimbursement, and the ability to establish value relative to alternative treatments.

Emerging-Market Localization and Regional Manufacturing

Asia Pacific offers opportunities for market expansion through rising healthcare demand, broader access to vascular intervention, and the growth of domestic medical-device manufacturing. Countries such as China and India face a substantial burden of diabetes and cardiovascular disease, while Japan has an aging population and an established base of advanced medical care. These factors are increasing the need for effective diagnosis and treatment of peripheral vascular conditions.

Domestic manufacturers are also developing technologies tailored to regional clinical and commercial requirements. In 2026, MicroPort Endovastec's SunFlow Drug-Eluting Peripheral Stent System received China's NMPA Green Channel designation for innovative medical devices. The system incorporates a sustained-release coating and a stent design intended to balance flexibility, support, and delivery performance. The designation facilitates the regulatory review process but does not itself represent marketing approval.

For international manufacturers, regional partnerships and local production can improve distribution, supply-chain resilience, and access to healthcare providers. Domestic companies, meanwhile, can use their manufacturing capabilities and knowledge of local markets to strengthen their competitive position. Long-term success will depend on clinical validation, regulatory approval, affordability, and the ability to establish reliable distribution networks.

Product Type Insights

Polymer-based drug-eluting stents are anticipated to account for 52.1% of the market share in 2026. Their position reflects established clinical use, mature manufacturing capabilities, and physician familiarity with polymer-controlled drug delivery. Boston Scientific's Eluvia is a key example, using a polymer-based system to deliver paclitaxel in the superficial femoral and proximal popliteal arteries. Other established platforms include Medtronic's IN.PACT Admiral drug-coated technology and polymer-based drug-delivery platforms developed for peripheral intervention. FDA post-approval data for Eluvia reported 12-month primary patency of 83.2%, compared with 74.3% for bare-metal stents, supporting continued use of controlled drug delivery in femoropopliteal intervention.

Polymer-free drug-eluting stents are anticipated to be the fastest-growing product segment, supported by interest in delivering antiproliferative drugs without leaving a permanent polymer layer. Cook Medical's Zilver PTX is a prominent example, using a polymer-free paclitaxel coating for femoropopliteal disease. Bioresorbable drug-eluting scaffolds represent a smaller but strategically important segment, led by Abbott's Esprit BTK, which combines temporary mechanical support with everolimus delivery for below-the-knee disease. Hybrid and next-generation coating platforms are also emerging, with competition increasingly focused on drug-release control, scaffold performance, deliverability, and vessel healing.

Drug Type Insights

Sirolimus-eluting stents are anticipated to account for approximately 34.7% of the market share in 2026. Their position is supported by the established antiproliferative properties of sirolimus and the broader clinical experience associated with limus-family drugs. Examples include Cordis' sirolimus-based vascular technologies and emerging peripheral platforms that combine sirolimus delivery with advanced coating systems. Drug selection is increasingly linked to polymer composition, coating architecture, release duration, and the anatomical characteristics of the target vessel.

Everolimus-eluting stents are anticipated to be the fastest-growing drug segment, supported by their use in newer peripheral technologies and bioresorbable scaffolds. Abbott's Esprit BTK is the most prominent example, combining everolimus delivery with a resorbable scaffold for below-the-knee chronic limb-threatening ischemia. Paclitaxel remains important in femoropopliteal intervention through Eluvia and Zilver PTX, while zotarolimus and biolimus represent smaller segments. Future development is expected to focus on matching drug characteristics with scaffold materials and vessel-specific treatment requirements.

North America Drug Eluting Peripheral Stents Market Trends

North America is expected to be the leading regional market, accounting for approximately 40.6% of global revenue, with the U.S. driving demand through its large PAD population, advanced vascular-care infrastructure, reimbursement systems, and medical-device innovation. The ACC/AHA estimates that 10–12 million Americans over age 40 have PAD, sustaining demand for peripheral interventions. The FDA approval of Abbott's Esprit BTK in April 2024 expanded the U.S. market into below-the-knee resorbable drug-eluting technology, while subsequent product developments are broadening treatment options for complex disease.

U.S. Drug Eluting Peripheral Stents Market Trends

The U.S. market remains strongly evidence- and regulation-driven. FDA's assessment that available evidence did not support excess mortality associated with paclitaxel-coated PAD devices has reduced uncertainty around an important technology class. Boston Scientific's Eluvia continues to support clinical adoption through post-approval evidence, while the company's January 2025 agreement to acquire Bolt Medical demonstrates increasing interest in complementary technologies for calcified peripheral lesions. Bolt's intravascular lithotripsy platform is designed for lesion preparation, potentially strengthening integrated treatment portfolios around peripheral intervention.

Canada Drug Eluting Peripheral Stents Market Trends

Canada represents a smaller but established market supported by specialist vascular centers and regulated adoption of advanced devices. Health Canada previously authorized Eluvia, while its 2026 approvals included additional peripheral vascular technologies such as iVascular's iCover covered peripheral stent. These developments broaden the available device portfolio and indicate continued regulatory acceptance of sophisticated endovascular technologies.

Europe Drug Eluting Peripheral Stents Market Trends

Europe is a mature market supported by aging populations, specialized vascular services, and established minimally invasive treatment pathways. However, adoption varies across national reimbursement systems and procurement structures. The EU Medical Device Regulation and EUDAMED requirements increase the importance of clinical evidence, traceability, post-market surveillance, and regulatory capabilities, favoring manufacturers with established compliance infrastructure.

Germany Drug Eluting Peripheral Stents Market Trends

Germany is an important European market with a strong vascular-care ecosystem. Its updated peripheral arterial disease guideline, published in September 2024 and valid through September 2029, reinforces evidence-based diagnosis, treatment, and follow-up. This environment encourages manufacturers to demonstrate durable clinical outcomes rather than relying solely on device specifications, supporting demand for differentiated technologies in complex peripheral disease.

U.K. Drug Eluting Peripheral Stents Market Trends

The U.K. combines established vascular services with a strong health-technology assessment culture. NICE reviewed its PAD guidance again in 2026 and identified areas where emerging evidence could warrant future updates. This keeps clinical effectiveness and appropriate patient selection central to adoption. Consequently, drug-eluting stent manufacturers must demonstrate meaningful benefits alongside cost-effectiveness, particularly within NHS procurement.

Asia Pacific Drug Eluting Peripheral Stents Market Trends

Asia Pacific is the fastest-growing regional market, supported by expanding interventional capacity, rising cardiometabolic disease burden, improving healthcare infrastructure, and increasing domestic device manufacturing. China, Japan, India, South Korea, and Southeast Asia provide substantial opportunities as specialist vascular services expand.

China Drug Eluting Peripheral Stents Market Trends

China has a particularly large potential patient base. Domestic innovation is also becoming more visible. In May 2026, MicroPort Endovastec's SunFlow Drug-Eluting Peripheral Stent System entered China's NMPA Green Channel for innovative medical devices. Its dual-layer sustained-release coating and hybrid stent architecture illustrate the move toward locally developed peripheral DES technologies, although Green Channel designation is not marketing approval.

Japan Drug Eluting Peripheral Stents Market Trends

Japan offers a high-value market characterized by advanced cardiovascular infrastructure, an aging population, and strong adoption of minimally invasive technologies. Terumo's continued development of vascular-access technologies, including the May 2026 Japanese launch of TR Band Distal, reflects broader investment in procedures designed to improve vascular access and post-procedure management. Such infrastructure development can support wider adoption of sophisticated peripheral interventions as procedural capabilities expand.

The global drug eluting peripheral stents market is moderately concentrated, with established global manufacturers controlling the most commercially mature femoropopliteal platforms while newer companies build positions through differentiated coatings, resorbable scaffolds, and regional expansion.

Leading manufacturers are prioritizing clinical evidence, product durability, controlled drug delivery, longer lesion coverage, regulatory execution, and portfolio expansion. M&A increasingly adds complementary technologies such as intravascular lithotripsy, thrombectomy, embolic protection, and imaging. Regional manufacturers are combining cost-efficient production, localized regulatory strategies, and international distribution with differentiated peripheral technologies.

Key Industry Developments:

• In May 2026, MicroPort Endovastec's SunFlow Drug-Eluting Peripheral Stent System received NMPA Green Channel designation for innovative medical devices in China.
• In April 2025, Boston Scientific completed its acquisition of the remaining 74% stake in Bolt Medical, strengthening its cardiovascular portfolio with an intravascular lithotripsy platform designed to treat calcified coronary and peripheral artery disease.